BRCA2 and cancer: The increased risk of invasive pelvic serous cancer (PSC) of the ovary, fallopian tube or peritoneum in women carrying a germline mutation in the BRCA1 and BRCA2 cancer predisposition genes is well established, with a lifetime risk ranging from 31–54% and 6–27%, respectively [1–5].